Do noradrenergic reuptake inhibitors
affect serotonergic function in depression?
by
Cleare AJ, Murray RM, O'Keane V
Department of Psychological Medicine,
Institute of Psychiatry,
London, UK.
Psychopharmacology (Berl) 1997 Dec; 134(4):406-10

ABSTRACT

d-Fenfluramine, a specific 5-HT releasing agent without the catecholamine effects of d,l-fenfluramine, was used as a serotonergic neuroendocrine challenge in subjects with unipolar major depression. Prolactin and cortisol responses to 30 mg d-fenfluramine were measured in patients at baseline. Patients were then randomly assigned to treatment for 6 weeks with a specific noradrenergic reuptake inhibitor, a tricyclic antidepressant, or placebo. Response to antidepressant treatment was assessed, and patients underwent further testing with d-fenfluramine. Prolactin responses were increased by treatment, but this was independent of whether or not patients' depression responded to treatment. Seven patients were treated with a specific noradrenergic reuptake inhibitor. These patients showed a significant rise in 5-HT-mediated cortisol responses after treatment, independent of whether their depression improved. We conclude that antidepressants which selectively modify noradrenergic function also have effects on 5-HT function as measured by neuroendocrine testing.

SSRIs
NARIs
Options
Serotonin
Tryptophan
Reboxetine
Nefazodone
Mirtazapine
Venlafaxine
Fenfluramine
New antidepresants
Noradrenaline and serotonin
Noradrenergic plus serotonergic antidepressants
Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family